National Institute for Health and Care Excellence18h
Consultation on updated guideline to assess and prevent falls in older people
The draft updated guidance on assessing and preventing falls in older people and people aged 50 and over at higher risk opens ...
National Institute for Health and Care Excellence2d
First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE
First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...
National Institute for Health and Care Excellence2d
Published guidance, NICE advice and quality standards
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) TA1006 12 September 2024 12 September 2024 Evinacumab for treating homozygous familial hypercholesterolaemia ...
National Institute for Health and Care Excellence1mon
NICE-recommended digital therapies for depression and anxiety could free up thousands of NHS therapist hours
Demand for NHS Talking Therapies has reached an all-time high. The service received 1.82 million referrals in 2023/24. This is slightly higher than 2021/2022, and more than double the 884,000 received ...
National Institute for Health and Care Excellence7d
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years TSID 12046
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence12d
Iptacopan for treating complement 3 glomerulopathy ID6283
A list of downloadable documents created during development.
National Institute for Health and Care Excellence7d
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years TSID 12049
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence7d
Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height TSID 12070
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence15d
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...
National Institute for Health and Care Excellence7d
Pridopidine for treating Huntington's disease TSID 12052
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence8d
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [TS ID 12105]
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence11d
Iptacopan for treating complement 3 glomerulopathy ID6283
Suggested remit: To appraise the clinical and cost effectiveness of iptacopan within its marketing authorisation for treating complement 3 (C3) glomerulopathy.